Ye Fei, Huang Baoying, Zhao Li, Deng Yao, Ren Jiao, Tan Wenjie
National Health Commission (NHC) Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
China CDC Wkly. 2022 Jun 10;4(23):509-512. doi: 10.46234/ccdcw2022.112.
To identify Novaferon (Nova), a novel recombinant protein of interferon (IFN)-α, antiviral activity against ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Omicron variant .
Vero cells were infected with SARS-CoV-2 and Omicron variant in a biosafety level-3 laboratory. And viral replications were accessed using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR).
Results demonstrated that Nova has effective inhibition against ancestral SARS-CoV-2 and Omicron variant .
The effects of Nova need to be further tested in animal models. And large-scale randomized double-blind clinical trials are needed to reveal its potentially clinical application.
鉴定新型重组α干扰素（IFN）蛋白诺和复（Novaferon，Nova）对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）原始毒株及奥密克戎变异株的抗病毒活性。
在生物安全3级实验室中，用SARS-CoV-2原始毒株及奥密克戎变异株感染Vero细胞。采用定量实时逆转录聚合酶链反应（RT-PCR）检测病毒复制情况。
结果表明，Nova对SARS-CoV-2原始毒株及奥密克戎变异株具有有效的抑制作用。
Nova的作用需要在动物模型中进一步测试。需要开展大规模随机双盲临床试验以揭示其潜在的临床应用价值。
